Press Releases
Samsung Biologics records sales of KRW 101 billion and profits of KRW 10.5 billion in 3Q 2018
Samsung Biologics records sales of KRW 101 billion and profits of KRW 10.5 billion in 3Q 2018
2018. 10. 23(Tue)
Samsung Biologics Co.,Ltd. (CEO: Tae Han Kim) today announced its business performance for the third quarter in 2018. The company posted quarterly sales of KRW 101.1 billion and operating profits of KRW 10.5 billion.
Sales and operating profits fell by KRW 24.3 billion and 13.2 billion respectively QoQ due to a decrease in the utilization rate of Plant 1 and 2, driven by changes in production products.
Net loss records KRW 30.1 billion, reflecting the impact of the unrealized gains and losses of the company’s subsidiary Samsung Bioepis.
※ Samsung Biologics Financial Result 3Q 2018 (Billion KRW)
|
'18. 3Q |
'18. 2Q |
QoQ |
'17. 3Q |
YoY |
Sales |
101.1 |
125.4 |
-243(19.4%) |
127.5 |
-26.4(20.7%) |
Operating Profit |
10.5 |
23.7 |
-132(55.7%) |
20.5 |
-10(48.8%) |
Net Profit |
-30.1 |
-9.6 |
-205(213.5%) |
-31.7 |
+1.6(4.9%) |
Meanwhile, Samsung Biologics has secured CDMO contracts with 25 companies for 36 products up to now, which are sufficient to fully operate Plant 1 and 2 fully. Samsung is running its plants in accordance with the operation plan, including global manufacturing approvals etc.
In addition, Plant 3, the world largest single plant, became CGMP ready in October 1st, 2018 with securing volume required for initial operation.
- The End -
Samsung Biologics records sales of KRW 101 billion and profits of KRW 10.5 billion in 3Q 2018
2018. 10. 23(Tue)
Samsung Biologics Co.,Ltd. (CEO: Tae Han Kim) today announced its business performance for the third quarter in 2018. The company posted quarterly sales of KRW 101.1 billion and operating profits of KRW 10.5 billion.
Sales and operating profits fell by KRW 24.3 billion and 13.2 billion respectively QoQ due to a decrease in the utilization rate of Plant 1 and 2, driven by changes in production products.
Net loss records KRW 30.1 billion, reflecting the impact of the unrealized gains and losses of the company’s subsidiary Samsung Bioepis.
※ Samsung Biologics Financial Result 3Q 2018 (Billion KRW)
| '18. 3Q | '18. 2Q | QoQ | '17. 3Q | YoY |
Sales | 101.1 | 125.4 | -243(19.4%) | 127.5 | -26.4(20.7%) |
Operating Profit | 10.5 | 23.7 | -132(55.7%) | 20.5 | -10(48.8%) |
Net Profit | -30.1 | -9.6 | -205(213.5%) | -31.7 | +1.6(4.9%) |
Meanwhile, Samsung Biologics has secured CDMO contracts with 25 companies for 36 products up to now, which are sufficient to fully operate Plant 1 and 2 fully. Samsung is running its plants in accordance with the operation plan, including global manufacturing approvals etc.
In addition, Plant 3, the world largest single plant, became CGMP ready in October 1st, 2018 with securing volume required for initial operation.
- The End -